Staff Publications: May 2018

  1. Anari F, Ramamurthy C, Zibelman M. Impact of Tumor Microenvironment Composition on Therapeutic Responses and Clinical Outcomes in Cancer. Future Oncol. 2018;14(14):1409-1421. PMID: 29848096.
  2. Bauman J. Enhancing Communication between Oncology Care Providers and Patient Caregivers During Hospice. The Journal of Community and Supportive Oncology. 2018;16(2):e72-e80.
  3. Beck TN, Kharin LV, Kit OI, Dulaimi E, Boumber Y. Miliary Adenocarcinoma of the Lung Responds to Gefitinib and Afatinib. J Thorac Oncol. 2018;13(6):e95-e97. PMID: 29793652. Letter.
  4. Berry KE. Estimating Fluoroscopic Peak Skin Dose Using Manual Calculations. Health Phys. 2018;114(6):649-653. PMID: 29697515.
  5. Bertolo R, Autorino R, Simone G, et al. Outcomes of Robot-Assisted Partial Nephrectomy for Clinical T2 Renal Tumors: A Multicenter Analysis (Rosula Collaborative Group). Eur Urol. 2018;74(2):226-232. PMID: 29784191.
  6. Bevelacqua JJ, Mortazavi SMJ. Commentary: Human Pathophysiological Adaptations to the Space Environment. Front Physiol. 2017;8(JAN):1116. PMID: 29358922. PMC5766677.
  7. Blass BE, Iyer P, Abou-Gharbia M, et al. Design and Synthesis of Functionalized Piperazin-1yl-(E)-Stilbenes as Inhibitors of 17alpha-Hydroxylase-C17,20-Lyase (Cyp17). Bioorg Med Chem Lett. 2018;28(13):2270-2274. PMID: 29803730.
  8. Calvo E, Azaro A, Rodon J, et al. Hepatic Safety Analysis of Trabectedin: Results of a Pharmacokinetic Study with Trabectedin in Patients with Hepatic Impairment and Experience from a Phase 3 Clinical Trial. Invest New Drugs. 2018;36(3):476-486. PMID: 29177975.
  9. Churilla TM, Weiss SE. Emerging Trends in the Management of Brain Metastases from Non-Small Cell Lung Cancer. Curr Oncol Rep. 2018;20(7):54. PMID: 29736685.
  10. Colevas AD, Yom SS, Pfister DG, et al. Nccn Guidelines Insights: Head and Neck Cancers, Version 1.2018. J Natl Compr Canc Netw. 2018;16(5):479-490. PMID: 29752322.
  11. Cui D, Zhang BW, Matubayasi N, Levy RM. The Role of Interfacial Water in Protein-Ligand Binding: Insights from the Indirect Solvent Mediated Potential of Mean Force. J Chem Theory Comput. 2018;14(2):512-526. PMID: 29262255. PMC5897112. NIHMS955674.
  12. Cuttler JM, Mortazavi SMJ, Welsh JS, Doss M. Re: “Low-Dose Childhood Radiation Effects to the Thyroid Follow a Linear Dose-Response Trend and Persist Even 45+ Years after Exposure” (Clin Thyroidol 2017;29:235-236). Thyroid. 2018;28(5):679-680. PMID: 29132249. Letter.
  13. Di Meco A, Li JG, Barrero C, Merali S, Pratico D. Elevated Levels of Brain Homocysteine Directly Modulate the Pathological Phenotype of a Mouse Model of Tauopathy. Mol Psychiatry. 2018. PMID: 29728702.
  14. Doss M. Selective Focus on Rare Hematologic Malignancies Misleads Risk-Benefit Assessment of Radioiodine Therapy of Thyroid Cancer. J Clin Oncol. 2018;36(18):1883-1884. PMID: 29723093.
  15. Eilam-Frenkel B, Naaman H, Brkic G, et al. Microrna 146-5p, Mir-Let-7c-5p, Mir-221 and Mir-345-5p Are Differentially Expressed in Respiratory Syncytial Virus (Rsv) Persistently Infected Hep-2 Cells. Virus Res. 2018;251:34-39. PMID: 29733865.
  16. Fanale MA, Horwitz SM, Forero-Torres A, et al. Five-Year Outcomes for Frontline Brentuximab Vedotin with Chp for Cd30-Expressing Peripheral T-Cell Lymphomas. Blood. 2018;131(19):2120-2124. PMID: 29507077. PMC5946765.
  17. Feliciano JL, Le-Rademacher JG, Gajra A, et al. Do Older Patients with Non-Small Cell Lung Cancer Also Benefit from First-Line Platinum-Based Doublet Chemotherapy? Observations from a Pooled Analysis of 730 Prospectively-Treated Patients (Alliance Study A151622). J Geriatr Oncol. 2018;9(5):501-506. PMID: 29848457.
  18. Frost CJ, Andrulis IL, Buys SS, et al. Assessing Patient Readiness for Personalized Genomic Medicine. J Community Genet. 2018. PMID: 29804257.
  19. Fu X, Ju J, Lin Z, et al. Target Deletion of Complement Component 9 Attenuates Antibody-Mediated Hemolysis and Lipopolysaccharide (Lps)-Induced Acute Shock in Mice. Sci Rep. 2016;6:30239. PMID: 27444648. PMC4957234.
  20. Gabbasov R, Xiao F, Howe CG, et al. Nedd9 Promotes Oncogenic Signaling, a Stem/Mesenchymal Gene Signature, and Aggressive Ovarian Cancer Growth in Mice. Oncogene. 2018;37(35):4854-4870. PMID: 29773902. PMC6119087.
  21. Gerson JN, Ramamurthy C, Borghaei H. Managing Adverse Effects of Immunotherapy. Clin Adv Hematol Oncol. 2018;16(5):364-374. PMID: 29851932.
  22. Gettinger S, Hellmann MD, Chow LQM, et al. Nivolumab Plus Erlotinib in Patients with Egfr-Mutant Advanced Nsclc. J Thorac Oncol. 2018;13(9):1363-1372. PMID: 29802888.
  23. Giroux V, Stephan J, Chatterji P, et al. Mouse Intestinal Krt15+ Crypt Cells Are Radio-Resistant and Tumor Initiating. Stem Cell Reports. 2018;10(6):1947-1958. PMID: 29805107. PMC5993649.
  24. Goodwin RD, Cheslack-Postava K, Santoscoy S, et al. Trends in Cannabis and Cigarette Use among Parents with Children at Home: 2002 to 2015. Pediatrics. 2018;141(6). PMID: 29759986.
  25. Hernandez Borrero LJ, Sikder R, Lulla A, et al. Bcl-2 Protein Targeting by the P53/P21 Complex-Letter. Cancer Res. 2018;78(10):2770-2771. PMID: 29703721. Letter.
  26. Kapoor E, Benrubi D, Faubion SS. Menopausal Hormone Therapy in Gynecologic Cancer Survivors: A Review of the Evidence and Practice Recommendations. Clin Obstet Gynecol. 2018;61(3):488-495. PMID: 29762148.
  27. Koczwara B, Stover AM, Davies L, et al. Harnessing the Synergy between Improvement Science and Implementation Science in Cancer: A Call to Action. J Oncol Pract. 2018;14(6):335-340. PMID: 29750579. PMC6075851.
  28. Koh WJ, Abu-Rustum NR, Bean S, et al. Uterine Neoplasms, Version 1.2018, Nccn Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16(2):170-199. PMID: 29439178.
  29. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. Mega X: Molecular Evolutionary Genetics Analysis across Computing Platforms. Mol Biol Evol. 2018;35(6):1547-1549. PMID: 29722887. PMC5967553.
  30. Kumar SK, Callander NS, Alsina M, et al. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. J Natl Compr Canc Netw. 2018;16(1):11-20. PMID: 29295877.
  31. Lee MH, Chakhtoura M, Sriram U, Caricchio R, Gallucci S. Conventional Dcs from Male and Female Lupus-Prone B6.Nzm Sle1/Sle2/Sle3 Mice Express an Ifn Signature and Have a Higher Immunometabolism That Are Enhanced by Estrogen. J Immunol Res. 2018;2018:1601079. PMID: 29850618. PMC5925037.
  32. Li X, Wang L, Fang P, et al. Lysophospholipids Induce Innate Immune Transdifferentiation of Endothelial Cells, Resulting in Prolonged Endothelial Activation. J Biol Chem. 2018;293(28):11033-11045. PMID: 29769317. PMC6052225.
  33. Liang H, Zhou G, Ge Y, et al. Elucidating the Inhibition of Peptidoglycan Biosynthesis in Staphylococcus Aureus by Albocycline, a Macrolactone Isolated from Streptomyces Maizeus. Bioorg Med Chem. 2018;26(12):3453-3460. PMID: 29805074. PMC6008248.
  34. Lindsay T, Movva S. Role of Molecular Profiling in Soft Tissue Sarcoma. J Natl Compr Canc Netw. 2018;16(5):564-571. PMID: 29752329.
  35. Liu H, Kiseleva AA, Golemis EA. Ciliary Signalling in Cancer. Nat Rev Cancer. 2018;18(8):511-524. PMID: 29802351.
  36. Liu H, Sun Q, Sun Y, et al. Melk and Ezh2 Cooperate to Regulate Medulloblastoma Cancer Stem-Like Cell Proliferation and Differentiation. Mol Cancer Res. 2017;15(9):1275-1286. PMID: 28536141.
  37. Ma GX, Shive SE, Zhang G, et al. Evaluation of a Healthy Chinese Take-out Sodium-Reduction Initiative in Philadelphia Low-Income Communities and Neighborhoods. Public Health Rep. 2018;133(4):472-480. PMID: 29846132. PMC6055292.
  38. Maifrede S, Nieborowska-Skorska M, Sullivan-Reed K, et al. Tyrosine Kinase Inhibitor-Induced Defects in DNA Repair Sensitize Flt3(Itd)-Positive Leukemia Cells to Parp1 Inhibitors. Blood. 2018;132(1):67-77. PMID: 29784639. PMC6034642.
  39. Manne S, Kashy DA, Zaider T, et al. Interpersonal Processes and Intimacy among Men with Localized Prostate Cancer and Their Partners. J Fam Psychol. 2018;32(5):664-675. PMID: 29771551. PMC6072581.
  40. Mei L, Du W, Idowu M, von Mehren M, Boikos SA. Advances and Challenges on Management of Gastrointestinal Stromal Tumors. Front Oncol. 2018;8:135. PMID: 29868467. PMC5949718.
  41. Morrison C, Pabla S, Conroy JM, et al. Predicting Response to Checkpoint Inhibitors in Melanoma Beyond Pd-L1 and Mutational Burden. J Immunother Cancer. 2018;6(1):32. PMID: 29743104. PMC5944039.
  42. Mortazavi SMJ. Comment on ‘Domestic Light at Night and Breast Cancer Risk: A Prospective Analysis of 105 000 UK Women in the Generations Study’. Br J Cancer. 2018. PMID: 29769746. PMC5988714.
  43. Mortazavi SMJ. Comments on “Radiological Protection for Pregnant Women at a Large Academic Medical Cancer Center”. Phys Med. 2018;47:144. PMID: 29032028.
  44. Moten AS, Lango MN, Goel N, Goldberg AJ. Regional Diagnostic Rates, Treatments, and Outcomes among Patients with Invasive Ductal Carcinoma. J Surg Res. 2018;229:114-121. PMID: 29936977.
  45. Mukherjee S, Pantelopulos GA, Voelz VA. Markov Models of the Apo-Mdm2 Lid Region Reveal Diffuse yet Two-State Binding Dynamics and Receptor Poses for Computational Docking. Sci Rep. 2016;6:31631. PMID: 27538695. PMC4990920.
  46. Oliver JS, Allen RS, Eichorst MK, et al. A Pilot Study of Prostate Cancer Knowledge among African American Men and Their Health Care Advocates: Implications for Screening Decisions. Cancer Causes Control. 2018;29(7):699-706. PMID: 29804218.
  47. Pang M, Bartel MJ, Brand EC, et al. Outcome of Long Benign Esophageal Strictures Undergoing Endoscopictherapy: A Tertiary Center Experience. Dis Esophagus. 2018. PMID: 29718161.
  48. Patel NR, Piroyan A, Ganta S, et al. In Vitro and in Vivo Evaluation of a Novel Folate-Targeted Theranostic Nanoemulsion of Docetaxel for Imaging and Improved Anticancer Activity against Ovarian Cancers. Cancer Biol Ther. 2018;19(7):554-564. PMID: 29737910. PMC5989790.
  49. Patel R, Scheinfeldt LB, Sanderford MD, et al. Adaptive Landscape of Protein Variation in Human Exomes. Mol Biol Evol. 2018;35(8):2015-2025. PMID: 29846678. PMC6063297.
  50. Patel SA, Ng M, Nardello SM, Ruth K, Bleicher RJ. Immediate Breast Reconstruction for Women Having Inflammatory Breast Cancer in the United States. Cancer Med. 2018. PMID: 29761885. PMC6051180.
  51. Ristau BT, Manola J, Haas NB, et al. Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the Assure (Ecog-Acrin 2805) Adjuvant Trial. J Urol. 2018;199(1):53-59. PMID: 28728992. PMC5800986.
  52. Ristau BT, Smaldone MC. Editorial Comment. J Urol. 2018;199(4):914. PMID: 29287168.
  53. Santucci-Pereira J, Pogash TJ, Patel A, et al. Aspirin Abrogates Impairment of Mammary Gland Differentiation Induced by Early in Life Second-Hand Smoke in Mice. Carcinogenesis. 2018. PMID: 29788174. PMC6067120.
  54. Saxon B, Bass SB, Wright T, Panick J. Ebola and the Rhetoric of US Newspapers: Assessing Quality Risk Communication in Public Health Emergencies. Journal of Risk Research. 2018:1-14.
  55. Schuetze SM, Bolejack V, Thomas DG, et al. Association of Dasatinib with Progression-Free Survival among Patients with Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib. JAMA Oncol. 2018;4(6):814-820. PMID: 29710216. PMC6145709.
  56. Shah PH, Alom MA, Leibovich BC, et al. The Temporal Association of Robotic Surgical Diffusion with Overtreatment of the Small Renal Mass. J Urol. 2018. PMID: 29792881.
  57. Shi X, Ba R, You H, et al. A Rare Case of B-Lymphoproliferative Disorder with Villous Lymphocytes Harboring T(8;14)(Q24;Q32) Translocation. Front Med. 2018;12(3):324-329. PMID: 29075958.
  58. Siminoff LA, Wilson-Genderson M, Gardiner HM, Mosavel M, Barker KL. Consent to a Postmortem Tissue Procurement Study: Distinguishing Family Decision Makers’ Knowledge of the Genotype-Tissue Expression Project. Biopreserv Biobank. 2018. PMID: 29746160. PMC5995262.
  59. Sun M, Marconi L, Eisen T, et al. Adjuvant Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. Eur Urol. 2018. PMID: 29784193.
  60. Sun Y, Johnson C, Zhou J, et al. Uremic Toxins Are Conditional Danger- or Homeostasis-Associated Molecular Patterns. Front Biosci (Landmark Ed). 2018;23:348-387. PMID: 28930551. PMC5627515. NIHMS907864.
  61. Tan CRC, Abdul-Majeed S, Cael B, Barta SK. Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib. Clin Pharmacokinet. 2018. PMID: 29802543.
  62. Tang B, Lee HO, An SS, Cai KQ, Kruger WD. Specific Targeting of Mtap-Deleted Tumors with a Combination of 2′-Fluoroadenine and 5′-Methylthioadenosine. Cancer Res. 2018;78(15):4386-4395. PMID: 29844120. PMC6072572.
  63. Timmerman RD, Paulus R, Pass HI, et al. Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings from the Nrg Oncology Rtog 0618 Trial. JAMA Oncol. 2018;4(9):1263-1266. PMID: 29852037. PMC6117102.
  64. von Massenhausen A, Tonnus W, Himmerkus N, et al. Correction To: Phenytoin Inhibits Necroptosis. Cell Death Dis. 2018;9(6):622. PMID: 29795371. PMC5967310.
  65. von Mehren M, Randall RL, Benjamin RS, et al. Soft Tissue Sarcoma, Version 2.2018, Nccn Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16(5):536-563. PMID: 29752328.
  66. Vyfhuis MAL, Bhooshan N, Molitoris J, et al. Corrigendum to “Clinical Outcomes of Black Vs. Non-Black Patients with Locally Advanced Non-Small Cell Lung Cancer” [Lung Cancer 114, (December 2017) 44-49]. Lung Cancer. 2018;116:105. PMID: 29289353.
  67. Warner WA, Lee TY, Fang F, et al. The Burden of Prostate Cancer in Trinidad and Tobago: One of the Highest Mortality Rates in the World. Cancer Causes Control. 2018;29(7):685-697. PMID: 29774450. PMC5999193.
  68. Whelan KA, Muir AB, Nakagawa H. Esophageal 3d Culture Systems as Modeling Tools in Esophageal Epithelial Pathobiology and Personalized Medicine. Cell Mol Gastroenterol Hepatol. 2018;5(4):461-478. PMID: 29713660. PMC5924738.
  69. Wong YN, Manola J, Hudes GR, et al. Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: Ecog-Acrin Cancer Research Group (E1898) Trial. Clin Genitourin Cancer. 2018;16(2):e315-e322. PMID: 29173976. PMC5975965.
  70. Zarin P, In TS, Chen EL, et al. Integration of T-Cell Receptor, Notch and Cytokine Signals Programs Mouse Gammadelta T-Cell Effector Differentiation. Immunol Cell Biol. 2018. PMID: 29754419.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s